45 citations,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
20 citations,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
32 citations,
December 2018 in “Cytokine” Type I interferons play a key role in the development of various skin diseases.
July 2023 in “Journal of skin and stem cell” Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.
37 citations,
May 2004 in “Multiple Sclerosis Journal” The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.